Homepage Top Section1

The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The

Headquartered in California, Abide has developed a platform to discover potent and selective serine hydrolase inhibitors. The platform is used by the company to identify, develop, and validate

Trelegy Ellipta is a once-daily single inhaler triple therapy, which includes fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI). Fluticasone is an inhaled corticosteroid, while umeclidinium is a

Under the collaboration, Iktos virtual drug design technology will be implemented and applied to various Janssen small molecule drug discovery programs. The French firm will collaborate with the

SLE, simply referred as lupus, is a serious chronic disease that causes inflammation and damage to different body tissues and organs. The FDA provided priority review designation to

Smart Pharma will operate Smart-ACT, a computational repurposed drug discovery, modeling and validation platform, which uses latest technology for systematic screening of existing approved drug molecules against certain

The Israeli pharma came to the decision after a pre-specified futility analysis showed that fremanezumab was unlikely to meet the primary endpoint of a phase 3 trial in

Both firms have announced that top-line results from a phase 3 study assessing tanezumab 2.5mg and 5mg. Tanezumab is an investigational monoclonal antibody, which works by selectively targeting,

As per terms of the deal, twoXAR will apply its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms